

## REMARKS


In the Office Action dated May 5, 2006, the Examiner has set forth a requirement for restriction under 35 U. S. C. § 121. The Examiner contends that *“Group I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical feature”*. The Examiner reasoned that *“the technical feature of the invention of Group I is the transgenic animal, whereas the technical feature of Group II is the cell. Thus, there is no special technical feature linking the inventions of Group I and II”*.

Applicants respectively traverse this restriction. The cell in Claim 11 is extracted from the transgenic animal as described in accordance with any one of Claims 1-9. Therefore, the cell in Claim 11 and the transgenic animal have the same genetic makeup and share the same technical feature. Transgenic animal in Group I is merely sum of the cells, one of which is being claimed in Group II. Thus, the Groups I and II shall be properly examined together.

In view of the foregoing comments, it is respectively urged that the Examiner reconsider both Group I, Claims 1-10, 13, and Group II, Claims 11, 12, and 14.

The Commissioner is authorized to charge any fees or credit any overpayment necessitated by this response to Deposit Account No. 18-1982.

Respectfully submitted,

  
Xuhong Sunny Wang, Reg. No. 54,524  
Patent Agent for Applicant

sanofi-aventis U.S. LLC  
Patent Department  
Route #202-206 / P.O. Box 6800  
Bridgewater, NJ 08807  
Telephone (908) 231-3648  
Telefax (908) 231-2626

Docket No. ST99040 US PCT